
Remission Antibodies Point to a New CAR T Strategy Against Acute Myeloid Leukemia
Researchers at Memorial Sloan Kettering say antibodies found in acute myeloid leukemia patients who achieved long-term remission after bone marrow transplant helped reveal a new CAR T cell target that appears on leukemia
- Researchers used antibodies from AML patients in long-term remission after bone marrow transplant to identify a new target.
- The target, U5 snRNP200, appears on the surface of leukemia cells in about half of AML patients but is usually found inside the nucleus.


















